Everolimus Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 0.75 mg, 1.25 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg
Reference Brands: Zortress, Afinitor(US & EU)
Category:
Immune Disorder
Everolimus inhibits mTOR, blocking cell growth, proliferation, and survival. It effectively treats cancers, such as neuroendocrine tumors, breast cancer, and renal cell carcinoma, and prevents organ rejection in transplants. Benefits include targeted therapy, improved progression-free survival, and manageable side effects, supporting long-term disease management.
Everolimus tablets is available in Tablet
and strengths such as 0.75 mg, 1.25 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Everolimus tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Everolimus tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Everolimus tablets, marketed as Afinitor and Zortress, are approved in the US by the FDA and in the EU via EMA for various indications including cancer and transplant rejection. Regulatory approval requires a comprehensive dossier containing clinical trial data, manufacturing details, safety, efficacy, and pharmacovigilance strategies. In the US, FDA review involves stringent evaluation of clinical and quality data, while the EMA ensures compliance with regional standards. For guidance on dossier preparation, regulatory pathways, and market accession, visit PharmaTradz. Ensuring thorough regulatory compliance is critical for the safe, effective, and timely approval of everolimus tablets worldwide, supporting optimal patient outcomes in oncology and transplantation.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing